Higher incidence of metabolic syndrome components in vitiligo patients: a prospective cross-sectional study

Tanacan, Efsun; Atakan, Nilgün

doi:10.1016/j.abd.2019.07.006

Cited by 45 publications

(124 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multiple mechanisms have been proposed for melanocyte destruction in vitiligo including genetics, autoimmune responses, oxidative stress, generation of inflammatory mediators, and melanocytorrhagy (Bergqvist & Ezzedine, 2020). Non‐segmental vitiligo, the commonest form of the disease, is postulated to be a systemic rather than a solely depigmenting skin disorder, having a strong association with several systemic and metabolic disturbances, namely; insulin resistance, lipid abnormalities, atherosclerotic cardiovascular disease, and metabolic syndrome (Ataş & Gönül, 2017; Tanacan & Atakan, 2020). This postulation still needs further verification, given the limited sample size of the supporting studies.…”

Section: Introductionmentioning

confidence: 99%

Support for increased cardiovascular risk in non‐segmental vitiligo among Egyptians: A hospital‐based, case–control study

Azzazi

Mostafa

Sayed

et al. 2020

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

Background Data have been accumulating in the past few years that identify vitiligo as a disorder with systemic implications. Results and methods In this hospital‐based, cross‐sectional, case–control study, 50 patients with non‐segmental vitiligo and 50 age‐ and sex‐matched controls underwent analysis of serum lipid profile, oxidative stress biomarkers and carotid duplex. Hydrogen peroxide (H2O2) and malondialdehyde (MDA) were significantly higher in patients than controls (p‐value < .001, <.001, respectively); on the other hand, total antioxidant capacity (TAC) was significantly lower in patients than controls (p‐value = .001). A significantly higher percentage of patients had hypercholesterolemia and borderline high, high or very high levels of LDL‐C, compared to controls (p‐value = .001 and .001, respectively). Atherosclerotic plaques and increased common carotid intima media thickness were significantly detected in patients versus controls. Discussion Results of the present study suggest that a subset of patients with vitiligo are at a higher risk of developing dyslipidemia and atherosclerosis, which might increase their future risk for the development of cardiovascular disease. Confirmation of these findings would subsequently influence investigative and the treatment strategies in the management plan of vitiligo patients in the near future. Significance Vitiligo patients might be at a higher risk of developing dyslipidemia and atherosclerosis, which might increase their risk for the development of cardiovascular disease necessitating prophylactic measures to improve prognosis. Our results might influence the investigative and treatment strategies in the management plan of vitiligo patients in the near future.

show abstract

Section: Introductionmentioning

confidence: 99%

Support for increased cardiovascular risk in non‐segmental vitiligo among Egyptians: A hospital‐based, case–control study

Azzazi

Mostafa

Sayed

et al. 2020

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

show abstract

“…Vitiligo is a complex multifactorial disease that results from a complex interaction between environmental, genetic, neural, and immune factors. The psychological impact of vitiligo can be distressing especially among young adults 1 …”

Section: Introductionmentioning

confidence: 99%

Therapeutic implications of assessment of serum zinc levels in patients with vitiligo: A patient controlled prospective study

Zaki

Nada

Elshahed

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Vitiligo is an autoimmune disease characterized by patches of depigmentation. Zinc is an antiapoptotic molecule that exhibits antioxidant properties. The study aimed to investigate the serum levels of zinc in vitiligo patients compared to healthy controls and to whether exists a correlation between disease severity and serum levels of zinc. Fifty patients with vitilgo (group A) and 50 age and sex matched healthy controls (group B) were recruited and serum zinc level was measured using atomic absorption spectrophotometry and results were compared and correlated to each other and to disease severity and extension. The mean serum zinc levels in group A was 50.93 ± 11.02 in comparison to a mean of 77.09 ± 12.16 in group B (P = .049, T = −1.993). Vitiligo area severity index (VASI) scores in the vitiligo group ranged from 0.5 to 27 with a mean ± SD of (9.19 ± 4.47). A high statistically significant negative correlation was demonstrated between serum zinc levels and the extension of vitiligo (P value = .0001 and R value = − 0.835). A significant association exists between vitiligo and serum zinc levels. Serum zinc levels correlated negatively with vitiligo disease severity and extension. Zinc supplementation and use can be of potential importance in setting vitiligo treatment protocols.

show abstract

“…A study by Al Houssein et al found a significantly increased risk of diabetes and dyslipidemia and an increased risk of developing obesity and renal injuries in vitiligo patients [ 28 ]. Tanacan et al also found an increased frequency of metabolic syndrome in patients with vitiligo [ 1 ]. Sharma et al, in their study, found the prevalence of impaired glucose tolerance and significantly high levels of triglyceride and low levels of HDL in patients than in controls [ 29 ].…”

Section: Reviewmentioning

confidence: 99%

“…It is characterized by white patches on the skin. Around 0.1-2% of the world’s population is affected by the disease, irrespective of race and sex [ 1 ]. The disorder has been reported to have a high incidence in the second and third decade of life [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

“…While insulin resistance is believed to be the major factor involved in developing metabolic syndrome [ 7 ], oxidative stress has been suggested to cause the disorder by some studies [ 3 ]. Metabolic syndrome has become increasingly prevalent, with one-quarter of the adult population being affected [ 1 ]. Metabolic syndrome is associated with an increased risk of myocardial infarction, stroke, and diabetes [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator

Verma¹,

Hussain²,

Namiq³

et al. 2021

Cureus

View full text Add to dashboard Cite

Vitiligo is an autoimmune condition primarily affecting the skin where there is destruction of melanocytes characterized by pinkish-white patches on the skin. It is associated with other autoimmune diseases such as thyroid disease, rheumatoid arthritis, diabetes mellitus, and metabolic syndrome. Metabolic syndrome is a constellation of disorders including insulin resistance, hypertension, dyslipidemia, and obesity, and is considered a leading cause of cardiovascular morbidity. Simvastatin is a potent hypolipidemic drug that also possesses immunomodulating properties and is a common drug used in dyslipidemia and cardiovascular diseases. This study aimed to assess the association between vitiligo and metabolic syndrome and explore the immunomodulating properties of simvastatin for use in vitiligo. We reviewed various articles from PubMed, ResearchGate, and Google Scholar using different keywords and Medical Subject Headings and finalized 33 studies to be used in our review. The articles selected showed a positive association between vitiligo and metabolic syndrome or one of the component diseases of metabolic syndrome. The benefits of using simvastatin were also addressed by few articles attributing to its antioxidant and immunomodulating effect. However, there was no concrete explanation justifying the association between vitiligo and metabolic syndrome due to a limited number of studies and smaller sample size. Large-scale clinical trials should be conducted to evaluate the use of simvastatin as an immunomodulator in vitiligo to prevent possible metabolic complications.

show abstract

Higher incidence of metabolic syndrome components in vitiligo patients: a prospective cross-sectional study

Cited by 45 publications

References 27 publications

Support for increased cardiovascular risk in non‐segmental vitiligo among Egyptians: A hospital‐based, case–control study

Support for increased cardiovascular risk in non‐segmental vitiligo among Egyptians: A hospital‐based, case–control study

Therapeutic implications of assessment of serum zinc levels in patients with vitiligo: A patient controlled prospective study

Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator

Contact Info

Product

Resources

About